
## Veronica Zelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2417033/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuroprotective effects of human amniotic fluid stem cells-derived secretome in an ischemia/reperfusion model. Stem Cells Translational Medicine, 2021, 10, 251-266.	3.3	31
2	Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting. World Journal of Stem Cells, 2021, 13, 685-736.	2.8	3
3	Emerging Role of isomiRs in Cancer: State of the Art and Recent Advances. Genes, 2021, 12, 1447.	2.4	11
4	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers, 2021, 13, 4515.	3.7	6
5	Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes. Journal of Personalized Medicine, 2020, 10, 98.	2.5	16
6	Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. International Journal of Molecular Sciences, 2020, 21, 8222.	4.1	4
7	Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 110.	8.6	79
8	Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. High-Throughput, 2020, 9, 1.	4.4	22
9	MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas. Anticancer Research, 2019, 39, 4085-4093.	1.1	11
10	The antiquity of hydrocephalus: the first full palaeo-neuropathological description. Neurological Sciences, 2019, 40, 1315-1322.	1.9	3
11	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. International Journal of Cancer, 2019, 145, 390-400.	5.1	40
12	Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. Endocrine Connections, 2019, 8, 1224-1229.	1.9	6
13	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. Breast, 2018, 38, 92-97.	2.2	23
14	Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy. Breast, 2018, 40, 85-91.	2.2	7
15	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. Frontiers in Oncology, 2018, 8, 583.	2.8	25
16	<i><scp>PIK</scp>3<scp>CA</scp></i> c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report. Clinical Case Reports (discontinued), 2018, 6, 1358-1363.	0.5	4
17	Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers. Oncotarget, 2018, 9, 19783-19792.	1.8	8
18	Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile. Oncotarget, 2018, 9, 32173-32181.	1.8	10

VERONICA ZELLI

#	Article	IF	CITATIONS
19	Wholeâ€exome sequencing and targeted gene sequencing provide insights into the role of <i>PALB2</i> as a male breast cancer susceptibility gene. Cancer, 2017, 123, 210-218.	4.1	31
20	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
21	EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations. Breast Cancer Research and Treatment, 2016, 160, 181-186.	2.5	6
22	Somatic alterations of targetable oncogenes are frequently observed in <i>BRCA1/2</i> mutation negative male breast cancers. Oncotarget, 2016, 7, 74097-74106.	1.8	8
23	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. European Journal of Cancer, 2015, 51, 2289-2295.	2.8	25